help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, P. W.
Right arrow Articles by Bosh, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, P. W.
Right arrow Articles by Bosh, T. K.

Am. J. Respir. Crit. Care Med., Vol 155, No. 4, Apr 1997, 1283-1289.

Quality of life changes in COPD patients treated with salmeterol

PW Jones and TK Bosh
Division of Physiological Medicine, St. George's Hospital Medical School, London, United Kingdom.

Changes in health-related quality of life (HRQoL) were evaluated in patients with chronic obstructive pulmonary disease (COPD) following treatment with placebo, salmeterol 50 microg twice a day or 100 microg twice a day by metered-dose inhaler. Patients completed the disease- specific St. George's Respiratory Questionnaire (SGRQ) and the Medical Outcomes Study Short Form 36 (SF-36) at baseline and after 16 wk of treatment. Data from 283 patients (95 patients in the placebo group and 94 in each salmeterol group) were available for HRQoL analysis. Apart from a small difference in ages, all treatment groups were well matched at baseline in terms of forced expiratory volume in one second (FEV1) and HRQoL scores. Compared with placebo, salmeterol 50 microg twice a day was associated with significant improvements in SGRQ "Total" and "Impacts" scores which exceeded the threshold for a clinically significant change. This was not seen with salmeterol 100 microg twice a day. Changes in SGRQ and SF-36 scores correlated. They also showed a weak but significant relationship with FEV1. This study has shown that a modest change in lung function may be associated with clinically significant gain in health and well-being in COPD patients.


This article has been cited by other articles:


Home page
ChestHome page
K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel
Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD
Chest, August 1, 2008; 134(2): 255 - 262.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
T Ringbaek, E Brondum, G Martinez, P Lange, and and Pulmonary Rehabilitation Research Group
Rehabilitation in COPD: the long-term effect of a supervised 7-week program succeeded by a self-monitored walking program
Chronic Respiratory Disease, May 1, 2008; 5(2): 75 - 80.
[Abstract] [PDF]


Home page
ChestHome page
G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin
Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review
Chest, May 1, 2008; 133(5): 1079 - 1087.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Brouillard, V. Pepin, J. Milot, Y. Lacasse, and F. Maltais
Endurance shuttle walking test: responsiveness to salmeterol in COPD
Eur. Respir. J., March 1, 2008; 31(3): 579 - 584.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. Langsetmo, R. W. Platt, P. Ernst, and J. Bourbeau
Underreporting Exacerbation of Chronic Obstructive Pulmonary Disease in a Longitudinal Cohort
Am. J. Respir. Crit. Care Med., February 15, 2008; 177(4): 396 - 401.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M. G Pearson
Breathing exercises for asthma: panacea or placebo?
Thorax, December 1, 2007; 62(12): 1033 - 1034.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Bourbeau, G. Ford, H. Zackon, N. Pinsky, J. Lee, and G. Ruberto
Impact on patients' health status following early identification of a COPD exacerbation
Eur. Respir. J., November 1, 2007; 30(5): 907 - 913.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. G. Pasipanodya, T. L. Miller, M. Vecino, G. Munguia, S. Bae, G. Drewyer, and S. E. Weis
Using the St. George Respiratory Questionnaire To Ascertain Health Quality in Persons With Treated Pulmonary Tuberculosis
Chest, November 1, 2007; 132(5): 1591 - 1598.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
C. H. Goss and A. L. Quittner
Patient-reported Outcomes in Cystic Fibrosis
Proceedings of the ATS, August 1, 2007; 4(4): 378 - 386.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Meguro, E. A. Barley, S. Spencer, and P. W. Jones
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire
Chest, August 1, 2007; 132(2): 456 - 463.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al.
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Ann Intern Med, April 17, 2007; 146(8): 545 - 555.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier
Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 144 - 149.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian
An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD
Chest, June 1, 2006; 129(6): 1693 - 1708.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
P. W. Jones
Health Status: What Does It Mean for Payers and Patients?
Proceedings of the ATS, May 1, 2006; 3(3): 222 - 226.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
E. F. M. Wouters
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. D. Lopez, K. Shibuya, C. Rao, C. D. Mathers, A. L. Hansell, L. S. Held, V. Schmid, and S. Buist
Chronic obstructive pulmonary disease: current burden and future projections
Eur. Respir. J., February 1, 2006; 27(2): 397 - 412.
[Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
B. R. Celli
Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism.
Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
V Brusasco, R Hodder, M Miravitlles, L Korducki, L Towse, and S Kesten
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
Thorax, January 1, 2006; 58(5): 399 - 404.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. H. Ryu, J. Moss, G. J. Beck, J.-C. Lee, K. K. Brown, J. T. Chapman, G. A. Finlay, E. J. Olson, S. J. Ruoss, J. R. Maurer, et al.
The NHLBI Lymphangioleiomyomatosis Registry: Characteristics of 230 Patients at Enrollment
Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. C. Donaldson, T. A. R. Seemungal, I. S. Patel, A. Bhowmik, T. M. A. Wilkinson, J. R. Hurst, P. K. MacCallum, and J. A. Wedzicha
Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD
Chest, October 1, 2005; 128(4): 1995 - 2004.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
W. Vincken
Bronchodilator treatment of stable COPD: long-acting anticholinergics
Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax, June 1, 2005; 60(6): 480 - 487.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Alvarez-Mon, M. Miravitlles, J. Morera, L. Callol, and J. L. Alvarez-Sala
Treatment With the Immunomodulator AM3 Improves the Health-Related Quality of Life of Patients With COPD
Chest, April 1, 2005; 127(4): 1212 - 1218.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Decramer, R Gosselink, M Rutten-Van Molken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, and W De Backer
Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 335 - 342.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 343 - 349.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. Laghi, A. Antonescu-Turcu, E. Collins, J. Segal, D. E. Tobin, A. Jubran, and M. J. Tobin
Hypogonadism in Men with Chronic Obstructive Pulmonary Disease: Prevalence and Quality of Life
Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 728 - 733.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. C. Seldin, J. J. Anderson, V. Sanchorawala, K. Malek, D. G. Wright, K. Quillen, K. T. Finn, J. L. Berk, L. M. Dember, R. H. Falk, et al.
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
Blood, September 15, 2004; 104(6): 1888 - 1893.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
The TORCH Study Group
The TORCH (TOwards a Revolution in COPD Health) survival study protocol
Eur. Respir. J., August 1, 2004; 24(2): 206 - 210.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. F. Donohue
Therapeutic Responses in Asthma and COPD: Bronchodilators
Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. D. Sprenkle, D. E. Niewoehner, D. B. Nelson, and K. L. Nichol
The Veterans Short Form 36 Questionnaire Is Predictive of Mortality and Health-Care Utilization in a Population of Veterans With a Self-Reported Diagnosis of Asthma or COPD
Chest, July 1, 2004; 126(1): 81 - 89.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W.T. McNicholas, P.M.A. Calverley, A. Lee, and J.C. Edwards
Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD
Eur. Respir. J., June 1, 2004; 23(6): 825 - 831.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Eur. Respir. J., June 1, 2004; 23(6): 932 - 946.
[Full Text] [PDF]


Home page
ChestHome page
S. D. Aaron, D. Fergusson, R. Dent, Y. Chen, K. L. Vandemheen, and R. E. Dales
Effect of Weight Reduction on Respiratory Function and Airway Reactivity in Obese Women
Chest, June 1, 2004; 125(6): 2046 - 2052.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
W D C Man, N Mustfa, D Nikoletou, S Kaul, N Hart, G F Rafferty, N Donaldson, M I Polkey, and J Moxham
Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD
Thorax, June 1, 2004; 59(6): 471 - 476.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones
Impact of preventing exacerbations on deterioration of health status in COPD
Eur. Respir. J., May 1, 2004; 23(5): 698 - 702.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M Miravitlles, M Ferrer, A Pont, R Zalacain, J L Alvarez-Sala, F Masa, H Verea, C Murio, F Ros, and R Vidal
Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study
Thorax, May 1, 2004; 59(5): 387 - 395.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
B J Smith, S L Appleton, A J Veale, H J McElroy, D Veljkovic, and L Saccoia
Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol
Chronic Respiratory Disease, April 1, 2004; 1(2): 63 - 69.
[Abstract] [PDF]


Home page
Chronic Respiratory DiseaseHome page
J A Wedzicha
Short burst oxygen therapy is helpful?
Chronic Respiratory Disease, April 1, 2004; 1(2): 101 - 103.
[PDF]


Home page
ChestHome page
C. E. Cox, J. F. Donohue, C. D. Brown, Y. P. Kataria, and M. A. Judson
Health-Related Quality of Life of Persons With Sarcoidosis
Chest, March 1, 2004; 125(3): 997 - 1004.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
E Monninkhofe, P Van der valk, T Schermer, J Van der palen, C Van herwaarden, and G Zielhuis
Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease
Chronic Respiratory Disease, January 1, 2004; 1(1): 7 - 16.
[Abstract] [PDF]


Home page
ChestHome page
D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Eur. Respir. J., December 1, 2003; 22(6): 912 - 919.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
N. K. Leidy, S. I. Rennard, J. Schmier, M. K. C. Jones, and M. Goldman
The Breathlessness, Cough, and Sputum Scale: The Development of Empirically Based Guidelines for Interpretation
Chest, December 1, 2003; 124(6): 2182 - 2191.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J Stolk, W H Ng, M E Bakker, J H C Reiber, K F Rabe, H Putter, and B C Stoel
Correlation between annual change in health status and computer tomography derived lung density in subjects with {alpha}1-antitrypsin deficiency
Thorax, December 1, 2003; 58(12): 1027 - 1030.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
B. R. Celli
A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease
JAMA, November 26, 2003; 290(20): 2721 - 2729.
[Full Text] [PDF]


Home page
JAMAHome page
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
JAMA, November 5, 2003; 290(17): 2301 - 2312.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Monninkhof, P. van der Valk, J. van der Palen, C. van Herwaarden, and G. Zielhuis
Effects of a comprehensive self-management programme in patients with chronic obstructive pulmonary disease
Eur. Respir. J., November 1, 2003; 22(5): 815 - 820.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. M. A. Calverley, S. Spencer, L. Willits, P. S. Burge, and P. W. Jones
Withdrawal From Treatment as an Outcome in the ISOLDE Study of COPD
Chest, October 1, 2003; 124(4): 1350 - 1356.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
N. A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, S. Davis, and T. Shah
The Efficacy and Safety of Fluticasone Propionate (250 {micro}g)/Salmeterol (50 {micro}g) Combined in the Diskus Inhaler for the Treatment of COPD
Chest, September 1, 2003; 124(3): 834 - 843.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. A Dougherty, B. L Didur, and L. S Aboussouan
Long-Acting Inhaled {beta}2-Agonists for Stable COPD
Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
P M A Calverley, P S Burge, S Spencer, J A Anderson, and P W Jones
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Thorax, August 1, 2003; 58(8): 659 - 664.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S Spencer and P W Jones
Time course of recovery of health status following an infective exacerbation of chronic bronchitis
Thorax, July 1, 2003; 58(7): 589 - 593.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. T. Ferguson, C. Funck-Brentano, T. Fischer, P. Darken, and C. Reisner
Cardiovascular Safety of Salmeterol in COPD
Chest, June 1, 2003; 123(6): 1817 - 1824.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J.R. Curtis and D.L. Patrick
The assessment of health status among patients with COPD
Eur. Respir. J., June 1, 2003; 21(41_suppl): 36S - 45s.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
D. G. Hackam
Treatment of chronic obstructive pulmonary disease: Combination or component therapy?
Can. Med. Assoc. J., May 13, 2003; 168(10): 1296 - 1297.
[Full Text] [PDF]


Home page
ThoraxHome page
W MacNee and P M A Calverley
Chronic obstructive pulmonary disease * 7: Management of COPD
Thorax, March 1, 2003; 58(3): 261 - 265.
[Abstract] [Full Text] [PDF]


Home page
DTBHome page
{blacktriangledown}Tiotropium for chronic obstructive pulmonary disease
DTB, February 1, 2003; 41(2): 15 - 16.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A.G.N. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, and X. Busquets
Systemic effects of chronic obstructive pulmonary disease
Eur. Respir. J., February 1, 2003; 21(2): 347 - 360.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Eur. Respir. J., January 1, 2003; 21(1): 74 - 81.
[Abstract] [Full Text] [PDF]